The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2026
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Bagdasarova D.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Bolotina L.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia

Leukhina I.A.

National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

Shatalov P.A.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Revkova M.A.

National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

Veselovsky E.M.

National Medical Research Radiological Center

Karpulevich E.A.

Ivannikov Institute for System Programming of the Russian Academy of Sciences

Betelin V.B.

Ivannikov Institute for System Programming of the Russian Academy of Sciences;
Federal State Autonomous Institution Federal Scientific Center Research Institute for Systems Research of the National Research Center “Kurchatov Institute”

Avetisyan A.I.

Ivannikov Institute for System Programming of the Russian Academy of Sciences

Pochtovyi A.A.

Federal State Budgetary Institution “National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Gushchin V.A.

Federal State Budgetary Institution “National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University);
Federal State Budgetary Educational Institution of Higher Education Lomonosov

Logunov D.Yu.

Federal State Budgetary Institution “National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation

Gintsburg A.L.

Federal State Budgetary Institution “National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Shegai P.V.

National Medical Research Radiological Centre Ministry of Health of the Russian Federation;
Federal State Autonomous Educational Institution of Higher Education “Peoples’ Friendship University of Russia” (RUDN University)

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation;
National Medical Research Radiological Center of the Ministry of Health of Russian Federation;
Peoples friendship University of Russia (RUDN University)

mRNA technologies in treatment of oncological diseases: global experience of clinical trials and implementation in the Russian Federation

Authors:

Bagdasarova D.V., Bolotina L.V., Leukhina I.A., Shatalov P.A., Revkova M.A., Veselovsky E.M., Karpulevich E.A., Betelin V.B., Avetisyan A.I., Pochtovyi A.A., Gushchin V.A., Logunov D.Yu., Gintsburg A.L., Shegai P.V., Kaprin A.D.

More about the authors

Journal: P.A. Herzen Journal of Oncology. 2025;14(6): 69‑77

DOI: 10.17116/onkolog20251406169

Read: 2398 times

Contact the author
Table of contents

MRNA TECHNOLOGIES IN TREATMENT OF ONCOLOGICAL DISEASES: GLOBAL EXPERIENCE OF CLINICAL TRIALS AND IMPLEMENTATION IN THE RUSSIAN FEDERATION
MRNA TECHNOLOGIES IN TREATMENT OF ONCOLOGICAL DISEASES: GLOBAL EXPERIENCE OF CLINICAL TRIALS AND IMPLEMENTATION IN THE RUSSIAN FEDERATION

To cite this article:

Bagdasarova DV, Bolotina LV, Leukhina IA, et al. mRNA technologies in treatment of oncological diseases: global experience of clinical trials and implementation in the Russian Federation. P.A. Herzen Journal of Oncology. 2025;14(6):69‑77. (In Russ.)
https://doi.org/10.17116/onkolog20251406169

Подписка 2026 Онкология. Журнал им. П.А. Герцена (P.A. Herzen Journal of Oncology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
A review of the recent clinical studies on the treatment of patients with the chro­nic kidney disease et adva­nced stages. Russian Journal of Preventive Medi­cine. 2025;(8):110-114
Abstract:

Malignant neoplasms remain one of the leading causes of death worldwide, continuously driving the development and active implementation of new innovative treatments into clinical practice. This article provides a comprehensive review of the current status and prospects for the application of mRNA technologies in oncology, analyzing global clinical trial experience, the mechanism of action of therapeutic mRNA cancer vaccines, manufacturing processes, and the regulatory framework for the introduction of individual biotechnologically modified drugs (iBTMD) in the Russian Federation.

Keywords:

mRNA vaccines
tumor neoantigenes
cancer vaccines
personalized treatment
individual biotechnologically modified drugs (iBTMD)

Authors:

Bagdasarova D.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of the Ministry of Health of Russia

Bolotina L.V.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Radiology Research Center of Ministry of Russia

Leukhina I.A.

National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

Shatalov P.A.

National Medical Research Center of Radiology of the Ministry of Health of Russia

Revkova M.A.

National Medical Research Radiological Centre of the Ministry of Health of the Russian Federation

Veselovsky E.M.

National Medical Research Radiological Center

Karpulevich E.A.

Ivannikov Institute for System Programming of the Russian Academy of Sciences

Betelin V.B.

Ivannikov Institute for System Programming of the Russian Academy of Sciences;
Federal State Autonomous Institution Federal Scientific Center Research Institute for Systems Research of the National Research Center “Kurchatov Institute”

Avetisyan A.I.

Ivannikov Institute for System Programming of the Russian Academy of Sciences

Pochtovyi A.A.

Federal State Budgetary Institution “National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Gushchin V.A.

Federal State Budgetary Institution “National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University);
Federal State Budgetary Educational Institution of Higher Education Lomonosov

Logunov D.Yu.

Federal State Budgetary Institution “National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation

Gintsburg A.L.

Federal State Budgetary Institution “National Research Center of Epidemiology and Microbiology named after Honorary Academician N.F. Gamaleya” of the Ministry of Health of the Russian Federation;
Federal State Autonomous Educational Institution of Higher Education I.M. Sechenov First Moscow State Medical University of the Ministry of Health of the Russian Federation (Sechenov University)

Shegai P.V.

National Medical Research Radiological Centre Ministry of Health of the Russian Federation;
Federal State Autonomous Educational Institution of Higher Education “Peoples’ Friendship University of Russia” (RUDN University)

Kaprin A.D.

P.A. Herzen Moscow Oncology Research Institute — Branch of the National Medical Research Radiological Center of the Ministry of Health of the Russian Federation;
National Medical Research Radiological Center of the Ministry of Health of Russian Federation;
Peoples friendship University of Russia (RUDN University)

Received:

17.10.2025

Accepted:

28.10.2025

Close metadata

References:

  1. Global cancer burden is growing amidst mounting need for services [Internet]. (In Russ.) Available at: https://www.who.int/ru/news/item/01-02-2024-global-cancer-burden-growing--amidst-mounting-need-for-services.Accessed:13.10.2025.
  2. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-249.  https://doi.org/10.3322/caac.21660.
  3. Hegde PS, Chen DS. Top 10 Challenges in Cancer Immunotherapy. Immunity. 2020;52(1):17–35. 
  4. Dobosz P, Dzieciątkowski T. The Intriguing History of Cancer Immunotherapy. Front Immunol. 2019;10:2965. https://doi.org/10.3389/fimmu.2019.02965.
  5. Faghfuri E, Pourfarzi F, Faghfouri AH, Abdoli Shadbad M, Hajiasgharzadeh K, Baradaran B. Recent developments of RNA-based vaccines in cancer immunotherapy. Expert Opin Biol Ther. 2021;21(2):201–218.  https://doi.org/10.1080/14712598.2020.1815704.
  6. Van Nuffel AM, Wilgenhof S, Thielemans K, Bonehill A. Overcoming HLA restriction in clinical trials: immune monitoring of mRNA-loaded DC therapy. Oncoimmunology. 2012;1(8):1392–1394. https://doi.org/10.4161/onci.20926
  7. Wolff JA, Malone RW, Williams P, Chong W, Acsadi G, Jani A, et al. Direct gene transfer into mouse muscle in vivo. Science. 1990;247(4949 Pt 1):1465–1468. https://doi.org/10.1126/science.1690918
  8. Conry RM, LoBuglio AF, Wright M, Sumerel L, Pike MJ, Johanning F, et al. Characterization of a messenger RNA polynucleotide vaccine vector. Cancer Res. 1995;55(7):1397–1400 
  9. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines — a new era in vaccinology. Nat Rev Drug Discov. 2018;17(4):261–279.  https://doi.org/10.1038/nrd.2017.243
  10. Weber JS, Carlino MS, Khattak A, Meniawy T, Ansstas G, Taylor MH, et al. Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study. Lancet. 2024;403(10427):632–644.  https://doi.org/10.1016/S0140-6736(23)02268-7
  11. Lopez J, Powles T, Braiteh F, Siu LL, LoRusso P, Friedman CF, et al. Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial. Nat Med. 2025;31:152–164.  https://doi.org/10.1038/s41591-024-03334-7
  12. Rojas LA, Sethna Z, Soares KC, Olcese C, Pang N, Patterson E, et al. Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer. Nature. 2023;618:144–150.  https://doi.org/10.1038/s41586-023-06063-y
  13. A Study of Autogene Cevumeran (BNT122) in Combination With Atezolizumab in Patients With Untreated Advanced NSCLC [Internet]. Accessed: 13.10.202  https://clinicaltrials.gov/study/NCT05968326.
  14. Awad MM, Govindan R, Balogh KN, Spigel DR, Garon EB, Bushway ME, et al. Personalized neoantigen vaccine NEO-PV-01 with chemotherapy and anti-PD-1 as first-line treatment for non-squamous non-small cell lung cancer. Cancer Cell. 2022;40(9):1010–1026.e11.  https://doi.org/10.1016/j.ccell.2022.08.003
  15. A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People with High-Risk Melanoma (V940-001) [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT05933577
  16. A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002) (INTerpath-002) [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT06077760.
  17. A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (INTerpath-007) [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT06295809
  18. A Study of Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Renal Cell Carcinoma (V940-004). (INTerpath-004) [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT06307431
  19. A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT04526899
  20. A Clinical Trial Investigating the Safety, Tolerability, and Therapeutic Effects of BNT113 in Combination With Pembrolizumab Versus Pembrolizumab Alone for Patients With a Form of Head and Neck Cancer Positive for Human Papilloma Virus 16 and Expressing the Protein PD-L1 (AHEAD-MERIT) [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT04534205.
  21. A Trial to Learn How the Cancer Vaccine BNT116 in Combination With Cemiplimab Works and How Safe the Combination is in Adults With Advanced Non-small Cell Lung Cancer (EMPOWERVAX Lung 1) [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT05557591.
  22. A Phase II Clinical Trial Comparing the Efficacy of RO7198457 Versus Watchful Waiting in Patients With ctDNA-positive, Resected Stage II (High Risk) and Stage III Colorectal Cancer [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT04486378
  23. A Clinical Trial Evaluating TG4050 in Head and Neck Cancer [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT04183166
  24. Study of Intratumoral CV8102 in cMEL, cSCC, hnSCC, and ACC [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT03291002
  25. Clinical Study of Personalized mRNA Vaccine Encoding Neoantigen in Patients With Advanced Digestive System Neoplasms [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT03468244
  26. A Study of a Patient-Specific Neoantigen Vaccine in Combination With Immune Checkpoint Blockade for Patients With Metastatic Colorectal Cancer [Internet]. Accessed: 13.10.2025. https://clinicaltrials.gov/study/NCT05141721.
  27. Resolution of the Open Discussion “ATMPs: Specifics of Production, Registration, and Quality Control”. (International Congress “Drug Development and Registration”, Moscow, February 26–27, 2025). Drug Development and Registration. 2025;14(1):14-15. (In Russ.).
  28. Rocha LGDN, Guimarães PAS, Carvalho MGR, Ruiz JC. Tumor Neoepitope-Based Vaccines: A Scoping Review on Current Predictive Computational Strategies. Vaccines. 2024; 12(8), 836.  https://doi.org/10.3390/vaccines12080836.
  29. Haas BJ, Dobin A, Stransky N, Li B, Yang X, Tickle T, Regev A. STAR-Fusion: fast and accurate fusion transcript detection from RNA-Seq. BioRxiv. 2017; 120295. https://doi.org/10.1101/120295.
  30. Pertea, M., Pertea, G. M., Antonescu, C. M., Chang, T. C., Mendell, J. T., & Salzberg, S. L. (2015). StringTie enables improved reconstruction of a transcriptome from RNA-seq reads. Nature biotechnology, 33(3), 290-295.  https://www.nature.com/doifinder/10.1038/nbt.3122.
  31. Kodysh, J., & Rubinsteyn, A. (2020). OpenVax: an open-source computational pipeline for cancer neoantigen prediction. In Bioinformatics for Cancer Immunotherapy: Methods and Protocols (pp. 147-160). New York, NY: Springer US. https://doi.org/10.1007/978-1-0716-0327-7_10.
  32. Hundal J, Kiwala S, McMichael J, Miller C A, Xia H, Wollam A T, et al. pVACtools: a computational toolkit to identify and visualize cancer neoantigens. Cancer immunology research. 2020; 8(3), 409-420.  https://doi.org/10.1158/2326-6066.CIR-19-0401
  33. Rieder D, Fotakis G, Ausserhofer M, Rene G, Paster W, Trajanoski Z, Finotello F. nextNEOpi: a comprehensive pipeline for computational neoantigen prediction. Bioinformatics. 2022; 38(4):1131-1132. https://doi.org/10.1093/bioinformatics/btab759
  34. Jensen N, Barry A, Kelly AH. More-than-national and less-than-global: The biochemical infrastructure of vaccine manufacturing. Economy and Society. 2023; 52(1): 9-36.  https://doi.org/10.1080/03085147.2022.2087899
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.